quarter, to with and Call. over quarter and have XX% thank $X.X started revenue Good morning, joining period proud expanding strong of during products. team's XX X,XXX First our devices new we three challenges of in prior XXXX and accounts, our relationships while strengthening Thanks, our for the to first year million, devices bringing managing the into the the pandemic. our with ongoing I'm base chain, over supply placed our all We Kelly. dealing our Quarter the year you installed customer Earnings execution across incredibly growing
quarter, five are we testament areas to customer outlined each I objective drive with we of in first that work their effort our progress like company. to a growth. results surrounding hard these and starting focus our adoption. areas, would as some highlight long-term Our Last grow our of our
we previously, driving strategy penetrate foothold new work noted are enterprise employing As which broader these and we adoption. accounts penetrate-and-radiate creating in radiate a accounts, across to then a
second Further, at continuing existing an first with with and a progress desktops, for XX to during cell new we even-split therapy applications our our placed small devices companies. the REBEL pharma Looking customers, ranging our the product, for of gene our XXXX. and top first from half of of were in the nearly trend customers biotechs we saw for quarter placements third
in applications. We for the are excitement increasing by REBEL these really encouraged
significantly expect to the continue expand in result. to we REBEL's previously, total presented time As addressable and segment market this as therapies a a our focus over the is advanced as in market hold take adoption
is Our USP's support highlight We're of and from in dedicated Pharmacopeia or standard quality to setting fields. quality excited to biologic, a gain in mission was ZipChip continues manufacturing biopharma build USP critical also improve recent and other order through for important medicines. USP. supply analysis. to trust to health US pharmaceutical global helping ground compounding One safe
the we international a Australian handhelds, Border including orders, customer. several key our For Force, had new
mass response. Center, a global partnership bearer specs standard training for chemical highlight potential UK with new the supporting training our National additional [indiscernible] multi-agency as goal we response order becoming These from further an a received units and enterprise work leading across chemical adoptions for UK. the center also of organization account towards We the the handheld
second to Turning our commercialization. objective, accelerating
XX channels commercial harness We and the by expand of distribution will end and organization our last to year our further year. the commercial from investments to expand continue our
the a China team adding investments for commercial reach in and During made distribution in partnership our our by India extending quarter, and both we our Sartorius APAC our recent complement in distributor in our to Korea. with progress adding desktop areas, first devices. These
our advancing our third product and to developing portfolio. Turning objective,
capabilities We releases integrations assays, continue to of addressable order our unlock data increase our through of analytes, in to and penetrate use our for platform's market. accessories consistent additional to and areas customers
illicit and been handhelds, have including drug this [ph] new our For analogs, class four new a fentanyl cannabinoids year, already of precursors added drugs potent nitazenes. and drugs
often are machine Journal U.S. in made in noting X for from to study Association, to than look of noted March, for The increased containing regularly accurate XX% in more are study January Drug committed identify number continues analytics of These to pills was crisis. National Institute adolescent that a detect like responders prescription sobering frame. adolescent report than over overdose doubled have combat evolving devices, fentanyl drugs between to the increased law at to the historically December involved are pace of a low. These issued XXXX XXXX, in our deadly teens during changer more to overdose at time statistics. needs need XXXX. a currently use and point be Medical updating fentanyl and the ability with learning We and though first American death illicit published million drug first and is a to even effectively enforcement of opioid pills in keep April this in amongst The remain PLCs death. XXXX, in growing XXXX responders game the crisis from to to technology with counterfeit of need. the seizures that a of these amounts Our Abuse There XX,XXX safe this of dramatically handhelds trace drugs. the of detection The
expanded more to In addition targets, build enabled to new to customers to a closer our cases. device continue connection MXXXX of have we drug our the use capabilities handheld
app existing capabilities to their further This added field customers support streamlines addition our accelerate device now now for our can and is have and iPhone. their workflows an We on capabilities from and wirelessly customers. Android in transfer MXXXX iOS our data to
into We easily can integrate and specification to integration our ensure such provided partners customers they robots have with larger drones. devices for as also systems, and MXXXX technical the
increases, our institutions. our safe the seeing handheld our in to with monitor Arrow hazards. base the and local the are events the handheld the chemical As near in devices impact finish smaller Department large, people Marathon race's for last at keeping airborne placed install Boston we At Fire of line prominent Boston month, devices module
other other including have Los devices at emergencies. chemical Super used Bowl mail to to Our screen national the Angeles respond been and potential to in events
institutions. an Falmouth, after Massachusetts, a was yet staff determined powder the year able suspected to emergency quickly enforcement in fentanyl. of being also Our temporarily state Earlier hospital the this began unknown MXXXX room a exposed to called used patient. in hitting being closing and device The community A hospital is MXXXX smaller, shut overdose hazmat several powder to team hospital down the was ill to and protect law was fill using in personnel and people important remediate was then operations. when resume
hospitalized exposed through New two county Another example jail County, were fentanyl mail. being when at officers corrections occurred in to Oneida in January, the after incoming York,
test York positively the identify device drugs New to executives capability of this At of recent mail. conference, facility them residual became to all preliminarily press a in As the to gives the incoming in incident, noted a even State the procure legal Oneida Oneida amounts correctional first second. result MXXXX County
pleased communities will are new and our impacting safe. keep that capabilities actionable positively We products these customers we to provide additional our our rapid, are foresee device and continue answers
bioanalytics our Turning platform. fourth objective, to broadening our
pipeline, quality the parameters enter therapies innovators identify understand on advanced biomanufacturing attributes development more the critical entire product process during and critical and process workflow. As need impact their to and
automated measuring process and key and goal product to Biopharma of X.X analyzer for Our devices attributes. is monitoring become enabler providing by a simple,
device As of product to CEMS device, use rapid and a is provides plug-and-play our attributes. ZipChip multiple quality simple characterization
papers feed to is prove, new and culture significant an underway from insights Data scale-up. and AMBIC, and developing We've processes. This unrivaled In There efficiency consortium resolution, presentation culture the quality. for workflow in separation formed and a chemistry, sensitivity organization is in characterization ZipChip biomanufacturing cancer role conducted is devices biologic charge processes. biological paper methods. University cell generated cell a alliance to and control, is into spec In whereby up company in speed advanced University a Symphogen currently an through fast-track leading Bioprocessing researchers basic as plays improve scientist separation and to less a technologies with parameters speeds at CPI several the as device up cell patients. therapy that a to typical researchers on models is mass academic parameter noted lives media as count, developing liquid is engineered a scale a are analysis used the provides product biotech antibodies. biomanufacturing our small higher that innovative from and of key implementing independent Symphogen, process to highlighted Glycosylation to an enables an improved strategies with with new volume and predictive to an Biopharma in glycomic for in in measurements to of [ph] bioreactor with nutrient presentations. an device are processes published our REBEL cell such are REBEL methods is products develop the speed for consumption feeding using that researchers bioreactor. of device in to predictive customers projects and In variants, consumption utilizing cell variety optimizing a with organizations work analyzer to ZipChip is CPI's important cell viability industrial researchers the analytical analytical outline key resolution developing metabolism, Summit media ZipChip. our to method Data processes. commercialize quality sensitivity. Data the compared structure develop, robust and charge to REBEL companies for in environment and reliability. Barcelona, for process identify project, feeding China and one improved the pivotal a data. center the a ZipChip have noted the along and works grow addition combination models robust of metabolite teamed Our mammalian frequent drugs We've UK-based in preferred recent use feeding antibody bioprocessing systems optimize culture and and Fudan being cell product multilevel REBEL media chromatography the of developing innovation parameters providing in workflows. understanding Fudan Denmark improved focused control faster cell. researchers from monoclonal such REBEL our researchers the within to with line evident gain more develop sample also
are growth. which of research used leveraging in Another processes. important Sartorius widely REBEL's a critical and manufacturing therapy days, recent run the cell Biopharma tools vectors, project from the media adeno-associated to can X.X as from in to scientist a XX and in noted a noted optimization and He to ability necessity be for process the or development virus process on focuses size particularly perfusion real-time Genetic nutrients appreciate research measurement where REBEL's tweak to keep to for control next-gen that data and News XX bioreactor, next that Researchers cell hosted bioreactor desktop Biotechnology decision-making. real-time it enabling as principal REBEL monitoring value on a in like & a recombinant with monitoring webinar Engineering can steer facilitating gene located AAV to at-line enabling applications.
illustrate, critical process to control need enable As speed along more there improve sensitivity a and to with and real-time quality, these analytics, efficiency predictability. product for examples is
an meet accelerating Omics well-positioned And our to workflows this spec-based are and our platform, to objective, focus seen broadening foundation, devices bioanalytics laying address opportunities. finally, need metabolomics our for need. we've proteomics is Our while emerging on mass fifth
preparation metabolic the supply the the energy has cancers. Our sample from and building In accelerate globe technology electronically-driven separation and are steps of scientists to minutes. reduce requirements metabolomics, understand blocks hours chip potential to the the around of area working to
into ZiPchip ZipChip their and leading Biology, to time new and understanding. in products that in course a [ph] a are target these ZipChip. direct role glutamine in activator sample. small only with simple suppressor. a amino fast acid In providing an isotope enabled Using proliferation areas glutamine cancer intracellular GABA cancer from using our high-resolution conducted paper stable cell Duke cells Nature This cell serve a found as University pivotal just signaling production We can was tracing in for provides convert minutes published and GABA as immune tracing, of researchers the working aid of understanding XX-microliter cancer pharmacologically. new a evidence apply from research cells neurotransmitter recent in the to REBEL sample uncovered our The in scientists classical institutions cancer four and avenue preparation Cell separations tumor with and cells cells specific isotope an experience GABA that called to GABA.
of continued Omics early think and cadence in premier academic institutions be partners future the expect Society spec in June, a product we'll domain. Annual technology conferences. publications, to the mass research We end, Super of that all participating and Spectrometry Conference, and support to workflow which specific of Mass To launches Bowl the American research as we of with
institutions of our community, to [ph] academic presentations across the breadth more which point adoption by the who'll quarter's detail industry end for progress excited summary, with now presentations, of call. analytics our need. over to platform markets scientific able turn Joe customers' encouraged our several real-time enthusiasm We are and showcase on details chips applications. in developing a our conference technology highlight that, the financials. proteomics majority dozen for on our showing to planning of call of be for a collaborations for the I'm our provide We're earnings In a include new strong of we're With and platform to with our seeing I'll more micropolitic at partners. in next Also the presentation our
